Ahmed M. Salman
BSc, MSc, DPhil (Oxon)
Senior Immunologist-Vaccinologist, Fellow at Kellogg College and Instructor of Immunology
Dr. Ahmed M. Salman is a senior Immunologist/Vaccinologist working in Professor Adrian Hill’s Lab at the Jenner Institute in the Pre-erythrocytic Malaria group. Dr. Salman’s work is mainly to identify and assess new target antigens as vaccine candidates for infectious diseases caused by human and veterinary pathogens (including Malaria, COVID-19, T. Solium) using advanced immunology, vaccinology, molecular biology, genome editing, protein expression, and vaccine manufacturing technologies. The promising antigens are used as target antigens and expressed either as viral vector vaccines to mainly induce cellular immune response or as viral like particle (VLP) to induce a massive humoral immune response. Dr Salman took his BSc degree in Biochemistry at Ain Shams University in Cairo, Egypt in 2006 and from then until late 2011 was an instructor at the Department of Biochemistry, Faculty of Science, Ain Shams University. He completed a successful Master’s degree there on tuberculosis immunology in 2011. Most of that laboratory work was done while he worked at Statens Serum Institut in Copenhagen, Denmark, which is a major centre for mycobacterial vaccine research. In 2011 Dr Salman won a PhD scholarship at the European Virtual Malaria Institute programme “EVIMalaR” funded by the European Commission and EMBL at Heidelberg, Germany. In 2012 Dr. Salman started his D.Phil (PhD) in clinical medicine at the University of Oxford in Professor Adrian Hill’s Lab in Jenner Institute in collaboration with Professor Chris Janse and Professor Shahid Khan at the Leiden University Medical Centre in The Netherlands aiming for the identification and assessment of novel human malaria vaccines. Dr Salman produced his DPhil thesis in October 2014 and the DPhil degree in Clinical Medicine was awarded to him in May 2015 from the University of Oxford. The most important recent impact of his work has been on antigen down-selection for vaccine clinical trials. Three novel antigens have been funded to go to GMP manufacture and clinical trials. This work has been filed in a Malaria vaccination’s patent with an application number: PCT/GB2014/053077 (URL: https://patents.google.com/patent/WO2015052543A3/en). In addition he has a major contribution on another promising new P. vivax malaria sporozoite vaccine that is about to move to GMP manufacture and clinical trials. Since April 2020 Dr. Ahmed Salman became a part of the broad Jenner Institute research group working on the SARS-CoV-2 vaccine.
A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages.
Marin-Mogollon C. et al, (2019), Frontiers in Cellular and Infection Microbiology, 9
Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice
Brod F. et al, (2018), Frontiers in Immunology, 9
A Plasmodium berghei sporozoite-based vaccination platform against human malaria
Mendes AM. et al, (2018), npj Vaccines, 3
Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model
Yoshida K. et al, (2018), Scientific Reports, 8
Chimeric Plasmodium falciparum parasites expressing Plasmodium vivax circumsporozoite protein fail to produce salivary gland sporozoites
Marin-Mogollon C. et al, (2018), Malaria Journal, 17